AVCNF - Avicanna Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.3300
+0.0300 (+2.31%)
At close: 3:26PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.3000
Open1.3025
BidN/A x N/A
AskN/A x N/A
Day's Range1.2550 - 1.3300
52 Week Range0.5200 - 3.5300
Volume3,715
Avg. Volume4,750
Market Cap36.108M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update
      CNW Group

      Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update

      Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update

    • Avicanna to Postpone Reporting First Quarter 2020 Results Due to Delays Caused by COVID-19
      CNW Group

      Avicanna to Postpone Reporting First Quarter 2020 Results Due to Delays Caused by COVID-19

      Avicanna to Postpone Reporting First Quarter 2020 Results Due to Delays Caused by COVID-19

    • GlobeNewswire

      MediPharm Labs Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with Biopharmaceutical Leader Avicanna Inc.

      MediPharm Labs Corp., (LABS.TO) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that it has signed a multi-faceted strategic manufacturing agreement with Avicanna Inc. (TSX: AVCN) (AVCNF) (0NN.F) (“Avicanna”) involving licensed production, domestic and international distribution and intellectual property licensing. Avicanna is a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products. Under the agreement, which has an initial three-year term, MediPharm Labs will use the specialized contract manufacturing capabilities resident at its state-of-the-art Canadian production facility to produce Avicanna’s advanced Rho Phyto™ medical cannabis products and Pura Earth™ topicals under license for commercial sales through Medical Cannabis by Shoppers™.

    • Avicanna Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with World-Class Canadian Manufacturer MediPharm Labs
      CNW Group

      Avicanna Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with World-Class Canadian Manufacturer MediPharm Labs

      MediPharm Labs is a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products. Under the agreement, which has an initial three-year term, MediPharm Labs will use the specialized contract manufacturing capabilities resident at its state-of-the-art Canadian production facility to produce Avicanna's advanced Rho Phyto™ medical cannabis products and Pura Earth ™ topicals under license for commercial sales through Medical Cannabis by Shoppers™.

    • Avicanna Receives Government Support and Approval for First Ever Export of Hemp Seeds From Colombia
      CNW Group

      Avicanna Receives Government Support and Approval for First Ever Export of Hemp Seeds From Colombia

      TORONTO , May 7, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its cultivation subsidiary Santa Marta Golden Hemp S.A.S. ("SMGH"), it has received the approval from the Colombian government for the industrial export of hemp seeds to the US. The export, which is expected to be completed in the next two weeks, is the first ever export of cannabis seeds from Colombia and will be accomplished thanks to the support and coordination of the Colombian Institute of Agriculture (the "ICA"), and the Ministries of Agriculture and Justice for Colombia .

    • Avicanna Closes Non-Brokered Private Placement with Group of Strategic Investors and Announces Warrant Re-Pricing
      CNW Group

      Avicanna Closes Non-Brokered Private Placement with Group of Strategic Investors and Announces Warrant Re-Pricing

      Avicanna Closes Non-Brokered Private Placement with Group of Strategic Investors and Announces Warrant Re-Pricing

    • Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update
      CNW Group

      Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update

      Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update

    • Avicanna to Postpone Reporting Fourth Quarter and Full Year 2019 Results Due to Delays Caused by COVID-19
      CNW Group

      Avicanna to Postpone Reporting Fourth Quarter and Full Year 2019 Results Due to Delays Caused by COVID-19

      Avicanna to Postpone Reporting Fourth Quarter and Full Year 2019 Results Due to Delays Caused by COVID-19

    • Avicanna to Supply Australian Market with Cannabis-Based Medicinal Products Through Distribution Agreement with Cannvalate
      CNW Group

      Avicanna to Supply Australian Market with Cannabis-Based Medicinal Products Through Distribution Agreement with Cannvalate

      TORONTO , Feb. 24, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an importation and distribution agreement (the "Agreement") with Cannvalate Pty Ltd. ("Cannvalate"), to supply its Rho Phyto™ advanced medical cannabis products (the "Rho Products") to provide to patients under the Australian Therapeutic Goods Administration Special Access Scheme, as well cannabis active pharmaceutical ingredients (the "APIs"). Avicanna has also agreed to supply Cannvalate with a line of advanced cannabinoid phyto-therapeutic products that Avicanna has chosen to offer on a white-labelled basis (the "White-Label Products", collectively with the Rho Products and APIs, the "Products").

    • Avicanna Ranks Highest Amongst Global Cannabis Companies in the SAM Corporate Sustainability Assessment (CSA)
      CNW Group

      Avicanna Ranks Highest Amongst Global Cannabis Companies in the SAM Corporate Sustainability Assessment (CSA)

      TORONTO , Feb. 6, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has been rated the highest amongst global cannabis companies participating in the SAM Corporate Sustainability Assessment (CSA). The SAM Corporate Sustainability Assessment (CSA), established by RobecoSAM, is now issued by S&P Global. The 2020 Sustainability Yearbook that was published on January 30th by S&P Global, showcases the sustainability performance of some of the world's largest companies.

    • Avicanna Closes First Tranche of Private Placement
      CNW Group

      Avicanna Closes First Tranche of Private Placement

      TORONTO , Jan. 24, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (FSE:0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has closed the first tranche of an up to CAD$9,000,000 non-brokered private placement (the "Offering"). Under the first tranche of the Offering, the Company has issued an aggregate of 822,721 Units (the "Units") at a price of CAD$2.50 per Unit, for aggregate gross proceeds of approximately CAD$2.06 million . The Company has also received additional subscription agreements for an additional CAD$4 million , which it expects to close on in one or more further tranches on the same terms.

    • Avicanna Announces Appointment of Benjamin Leavenworth as Independent Director
      CNW Group

      Avicanna Announces Appointment of Benjamin Leavenworth as Independent Director

      TORONTO , Jan. 21, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the appointment of Benjamin Leavenworth to the Company's board of directors, effective immediately. Mr. Leavenworth has more than 20 years' experience in international business, with a focus on Latin America .

    • Avicanna Announces the Successful Completion of its Clinical Study Evaluating the Effect of an Emollient Cream Containing 0.5% Cannabidiol on Skin Hydration
      CNW Group

      Avicanna Announces the Successful Completion of its Clinical Study Evaluating the Effect of an Emollient Cream Containing 0.5% Cannabidiol on Skin Hydration

      TORONTO , Jan. 13, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced today its results from its first cosmetic clinical study, an open-label, randomized, passive-control study examining the impact of its Pura Earth™ topical cream containing 0.5% cannabidiol and 1% hemp oil on skin hydration. The investments that we've made in the research and development of the Pura Earth products is validated by these positive clinical results and further elevates the brand in the CBD derma-cosmetics market.

    • Avicanna Announces Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc., to Distribute Avicanna's Advanced and Evidence-based Medical Cannabis and Derma-Cosmetic Products Across Canada
      CNW Group

      Avicanna Announces Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc., to Distribute Avicanna's Advanced and Evidence-based Medical Cannabis and Derma-Cosmetic Products Across Canada

      TORONTO , Jan. 10, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced today that Medical Cannabis by Shoppers will be the exclusive Canadian distributor of the Rho PhytoTM medical cannabis and Pura EarthTM CBD derma-cosmetic product lines. Medical license holders in Canada will be able to purchase a consistent supply of Avicanna's advanced and evidence-based products starting in early-2020, including the Rho Phyto line, which includes sublingual sprays, oil drops, gels, creams, tablets and capsules.

    • Avicanna to Host Key Opinion Leader Meeting on the Use of Cannabinoids for the Treatment of Pain and Epilepsy
      CNW Group

      Avicanna to Host Key Opinion Leader Meeting on the Use of Cannabinoids for the Treatment of Pain and Epilepsy

      TORONTO , Dec. 6, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, today announced that it will host a Key Opinion Leader (KOL) meeting on the use of cannabinoids for the treatment of pain and epilepsy on December 12, 2019 in New York City . The event will feature a presentation by KOLs Hance Clarke, MD, PhD., University Health Network - Toronto General Hospital, and Amza Ali , MD, FRCP, MBA, Chief Medical Officer, Avicanna Inc., who will discuss how the use of cannabinoids can help to treat patients with severe pain and epilepsy.

    • Avicanna Receives DTC Eligibility for Common Shares on OTCQX
      CNW Group

      Avicanna Receives DTC Eligibility for Common Shares on OTCQX

      TORONTO , Dec. 5, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has obtained eligibility with the Depository Trust Company ("DTC") for its common shares listed in the United States on the OTCQX® Best Market.

    • Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group
      CNW Group

      Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group

      TORONTO , Dec. 3, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an importation and distribution agreement (the "Agreement") with Astral Health Ltd. ("Astral"), the operating subsidiary of the LYPHE Group Ltd ("LYPHE Group" or "LYPHE") to supply its cannabis-based medicinal products ("CBMPs") to patients in the United Kingdom under the MHRA 'specials' programme.

    • Avicanna's Rho Phyto Branded Products to be Available in California
      CNW Group

      Avicanna's Rho Phyto Branded Products to be Available in California

      TORONTO , Dec. 1, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) today announces that LC2019, Inc. ("LC2019"), the entity that holds a license to Avicanna's intellectual property in the United States , has advised Avicanna that it has entered into an agreement (the "License Agreement") with a subsidiary of Kings Garden Inc. ("Kings Garden"), a California based company, manufacturing the Kings Garden brand, with extensive experience in the cultivation, processing and manufacturing of high-end cannabis products, pursuant to which LC2019 will sub-license Avicanna's Rho PhytoTM brand and proprietary formulations (collectively, the "Rho Products") to Kings Garden.

    • Benzinga

      Avicanna Obtains Option To Acquire US Cannabis Operator

      Avicanna Inc. (TSX:AVCN) (OTC: AVCNF) announced Tuesday it has signed a license agreement with LC2019, Inc. under which the company will license specific proprietary formulations and brand elements to LC2019 for commercialization in the United States. “We are thrilled to secure a strategy that will allow us to enter the United States as soon as federally permissible and, in the interim, provide an opportunity for our brands and science-driven product formulations to establish themselves in one of the largest and most exciting global markets for cannabis products,” said Setu Purohit, President of Avicanna.

    • Avicanna Announces Option to Purchase Newly Formed US Cannabis Operator
      CNW Group

      Avicanna Announces Option to Purchase Newly Formed US Cannabis Operator

      TORONTO , Nov. 26, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has entered into a license agreement (the "License Agreement") with LC2019, Inc. ("LC2019") pursuant to which the Company has agreed to license certain proprietary formulations and brand elements to LC2019 for commercialization in the United States. As consideration for entering into the License Agreement, LC2019 and its shareholders have entered into a definitive option agreement (the "Option Agreement") that grants Avicanna the option (the "Option") to acquire 100 percent of the issued and outstanding shares of LC2019, with such Option to be exercisable in the event that cannabis cultivation, processing, distribution and possession‎ becomes federally legal in the United States (the "Triggering Event").

    • Benzinga

      Avicanna Trades Up On Q3 Results

      Down this line, the company posted a net loss for the quarter of CA$6.19 million versus a net loss of CA$2.07 million in the third quarter of 2018. During the third quarter, the company produced the first commercial batch of Pura Earth branded derma-cosmetic products; obtained a Health Canada cannabis research license; entered a joint venture with Sigma Analytical Services for the testing of cannabis and cannabis-based products in Colombia; signed an agreement with the University of Guelph to test the effectiveness of its products in various conditions; and added 120,000 square feet of cultivation space.

    • Avicanna Reports Third Quarter 2019 Financial Results
      CNW Group

      Avicanna Reports Third Quarter 2019 Financial Results

      During this time, we have initiated several revenue streams through our various product lines, which we expect to drive the Company's future growth. This first batch included a total of approximately 28,000 units of Pura Earth product manufactured using approximately 28 kilograms of the Company's purified cannabidiol ("CBD"). Clinical trials for Avicanna's branded derma-cosmetic line, Pura Earth, with the Centro de Atencion e Investigacion Medica CAIMED S.A.S., commenced during the quarter.

    • Avicanna Announces Voluntary Lock-Up Agreements for Key Insiders and Separation of CEO and Chairman Roles
      CNW Group

      Avicanna Announces Voluntary Lock-Up Agreements for Key Insiders and Separation of CEO and Chairman Roles

      TORONTO , Oct. 29, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, today announces that its executive officers and directors have entered into voluntary lock-up agreements to extend the term of their lock-up periods, affecting approximately 7.7 million shares. The Company also announces that Kyle Langstaff has stepped down as Vice President (Operations) and has concurrently entered into a lock-up agreement to restrict the disposition of his common shares. In addition, the Company's board of directors has separated the roles of Chairman and Chief Executive Officer.

    • Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom
      CNW Group

      Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom

      TORONTO , Oct. 24, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN)(OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. ("SMGH"), its majority owned subsidiary, has completed commercial exports of its Aureus™ brand of CBD-based products to South Africa and the United Kingdom (collectively, the "Jurisdictions"). The Aureus brand of products include an organic and sustainable line of plant-derived active pharmaceutical ingredients ("APIs") and bulk CBD formulations developed by Avicanna in collaboration with SMGH and Sativa Nativa S.A.S. ("Sativa Nativa"), which is also a majority owned subsidiary of Avicanna. These initial sales included the export of CBD isolate and 4% bulk formulation for CBD oil sublingual sprays.

    • Avicanna Announces Retail Launch of Pura Earth Derma-Cosmetics with Initial Roll-Out in Colombia
      CNW Group

      Avicanna Announces Retail Launch of Pura Earth Derma-Cosmetics with Initial Roll-Out in Colombia

      TORONTO , Oct. 21, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the retail launch of its Pura Earth™ derma-cosmetics line of CBD products, which are now available at approximately 59 high-end retail locations throughout Colombia , including Blind prestige beauty shops and Cromantic professional beauty markets. Avicanna's Anti-Aging Treatment, Anti-Aging Serum, Clear Skin Treatment and Intensive Skin Conditioning Treatment, which are the first four of the nine Pura Earth product lines, are currently available at retail. Additionally the Pura Earth line will be offered on e-commerce platforms, including Percos, Cormantic, and Blind, as well as Avicanna's own platform, which is currently dedicated to Pura Earth.